Inherited retinal disease is a common cause of visual impairment, and represents a highly heterogeneous group of conditions. Here, we present findings from a cohort of 722 individuals with inherited retinal disease, who have had whole genome sequencing (n=605), whole exome sequencing (n=72), or both (n=45) performed, as part of the NIHR-BioResource Rare Diseases research study. We identified pathogenic variants (single nucleotide variants, indels, or structural variants) for 404/722 (56%) individuals. Whole genome sequencing gives unprecedented power to detect three categories of pathogenic variants in particular: structural variants, variants in GC-rich regions, which have significantly improved coverage compared to whole exome sequencing, and variants in non-coding regulatory regions. In addition to previously reported pathogenic regulatory variants, we have identified a previously 4 unreported pathogenic intronic variant in the CHM in two males with choroideremia.
Introduction
Inherited retinal disease (IRD) describes a phenotypically heterogeneous group of conditions consequent upon dysfunction and/or degeneration of the neural retina or retinal pigment epithelium, resulting in visual impairment. IRD is the most common cause of severe visual impairment among working age individuals in the UK. 1 Determining the genetic cause of IRD in affected individuals allows accurate assessment of risk of the disease to other family members, provides useful prognostic information for affected individuals, and can provide much needed insight and understanding of the disease for those affected. Furthermore, genetic stratification of affected individuals is increasingly being used to direct specific treatment options, including clinical trials of medicines and restoration of protein function through gene therapy trials. 2 Whole exome sequencing (WES) of large cohorts of individuals has transformed research into rare Mendelian diseases in recent years by facilitating discovery of pathogenic variants, newly described disease-associated genes, and other insights into the genetic architecture of rare diseases. [3] [4] [5] Whole genome sequencing (WGS) has thus far typically been employed on a smaller scale, and has demonstrated advantages over other methods. 6, 7 Large-scale projects such as the Genomics England 100,000 Genome Project are also beginning to use WGS to investigate rare diseases. 8 IRD represents a particularly good clinical phenotype to provide comprehensive investigation by high-throughput sequencing technologies because it exhibits a high degree of phenotypic, genetic and allelic heterogeneity, with over 250 genes and loci associated with autosomal dominant, autosomal recessive, X-linked and mitochondrial inheritance (RetNet), and it is often difficult to predict the diseaseassociated gene from an individual's phenotype alone. 9 IRD is therefore among the many rare diseases that are increasingly being investigated through high-throughput sequencing. [10] [11] [12] [13] These technologies are also transforming clinical practice by being incorporated into diagnostic services. 14, 15 Most of these studies have used targeted pull-down of a predetermined panel of known genes, which are limited not only in that they only cover certain genes, but also because they cannot reliably detect structural variants (SVs). WES, on the other hand, is not limited to known diseaseassociated genes, but coverage is generally variable across the exome, negatively affecting variant detection compared to targeted gene panel testing. 16 PCR-free WGS should overcome the disadvantages of WES and targeted gene panels, although the remaining challenge will be in handling the large amount of data generated, and variant interpretation. Indeed, a recent study compared WGS to targeted gene panels and found that WGS improves the pathogenic variant detection rate by facilitating detection of SVs and variants in regulatory regions. 17 The aims of the current study were threefold. First, to identify pathogenic variants in a large cohort of individuals with IRD, including intractable cases in which previous investigations had not yielded a diagnosis. Second, to explore advantages and disadvantages of WGS as a tool with which to investigate IRD. To identify the likely ethnicity of each individual, a principal component analysis was performed on WGS data from individuals of various ethnicities in the 1000 genomes project with 20,000 single nucleotide variants (SNVs) using PLINK. 21 The location of the centre of the cluster of each ethnicity was then calculated, and a likely ethnicity assigned to each of the WGS samples based on the closest cluster.
Variant interpretation
To facilitate variant interpretation, a list of reported IRD-associated genes was assembled, including genes associated with syndromic forms of IRD or albinism, from various sources including RetNet and literature searches. This list was manually curated according to published evidence of pathogenicity to compile a shortlist of 224 high-confidence IRD-associated genes (table S1) . 22 To identify pathogenic variants, a two-step variant filtering protocol was designed, utilising automated filtering followed by manual review. For SNVs and indels, Manual review of all the variants that passed the automated filtering was then performed. The variant is considered to be pathogenic if it fulfils the following criteria.
First, the genotype and frequency of the variant is consistent with the expected mode of inheritance of the individual's family (if known), and with the expected mode of inheritance of the gene. Second, the phenotype of the individual is consistent with the phenotype known to be associated with the gene. Third, the variant is predicted to result in truncation of the protein, or it is predicted to be damaging to the protein using scores such as CADD, 26 or it has previously been reported as pathogenic in HGMD Pro. Fourth, the variant appears to be of good quality upon examination of the sequencing reads with Integrative Genomics Viewer (IGV). 27 Fifth, the variant affects the Ensembl canonical transcript or a known retinal transcript.
Variant confirmations
A subset of the pathogenic SNVs and indels was confirmed by Sanger sequencing using standard protocols. For SVs, Sanger sequencing was performed across the predicted breakpoints to generate a unique junction fragment sequence. Genotyping using HumanCoreExome-24 v1.0 BeadChip (Illumina) was also performed, followed by SV identification using GenomeStudio and cnvPartition software (Illumina).
Sequences of all primers are available on request.
Comparing coverage of WGS and WES datasets
Protein-coding regions of the Ensembl canonical transcript of each autosomal IRDassociated gene were split into 50bp bins. The mean GC% of each bin was calculated using data available from the UCSC genome browser. The mean coverage of each bin was calculated across a sample of 100 individuals with IRD in the NIHR BioResource Rare Diseases cohort (WGS data), and also in the ExAC cohort, for which per-base coverage has been previously published on 10% of the cohort. 24 We used the ExAC WES dataset for the comparison of the coverage of IRD-associated genes, rather than the WES data generated as part of this study, because ExAC was used as a frequency control set in this study, and because it is based on > 60,000 individuals. To identify the pathogenic variants, rare, coding, and high-quality variants, including large deletions, in 224 genes that are known to be associated with IRD, were considered. The likely cause of IRD was identified in 404/722 individuals, corresponding to a pathogenic variant detection rate of 56% ( 
Results

In
WGS improves coverage of GC-rich regions compared to WES
In the current study, we have observed increased power to detect variants in GC-rich regions. To assess the possible impact of this, we calculated the average coverage of exons of known IRD-associated genes, split into 50bp bins, in our WGS dataset and in the ExAC WES dataset. For exons of IRD-associated genes with a GC content of 45-65% the average coverage by read depth of sequence using WES is higher than for WGS. The calling of SNV exonic variants in this range is not significantly different for WES and WGS. Comparing WES from ExAC, we find significantly higher coverage in our WGS dataset in bins with GC <30% or >70%
( figure 4) . Additionally, the variability of coverage in our WGS data is much less than that of the ExAC dataset. This uniformity of coverage is one of the main factors that make WGS particularly powerful for SV detection. Calling SVs in WES where the variance of read depth is so great is unreliable ( figure 1A ).
Case study four illustrates the clinical relevance of this improvement in coverage.
Individual G004991 presented with Leber's congenital amaurosis. Pathogenic compound heterozygous variants were identified in the first coding exon of GUCY2D Furthermore, visual inspection of the sequencing reads using IGV demonstrates biallelic inheritance of the two variants, since they occur within 70 nucleotides and are never observed on the same 150bp read.
WGS allows identification of pathogenic variants in non-coding regions
In our cohort, three different pathogenic non-coding SNVs were identified. For example, in G008165, who presented with Stargardt disease, one intronic SNV was identified in ABCA4 in trans with a previously reported synonymous SNV, 224bp downstream of the cryptic acceptor site suggested that a cryptic exon could arise from this variant (figure 6).
To confirm this, we used RT-PCR amplification spanning exons 4-5 of CHM from G001372, G007713, and the heterozygous mother of G007713. This demonstrated a fragment approximately 200bp larger than expected (2 fragments in the heterozygous mother). Upon sequencing of the fragments, the predicted cryptic exon was confirmed. The variant is predicted to lead to a premature termination codon after 9 altered amino acid residues (p.S105Rfs*10).
Monoallelic variants in genes associated with a recessive mode of inheritance
Interpreting single heterozygous variants in recessive IRD-associated genes presents a challenge, as it is typically difficult to distinguish between a case in which . 17 This may reflect a combination of detailed specialist phenotyping to reduce phenocopies and the comprehensive exon and non-coding coverage achieved using WGS.
Identification of genes containing likely biallelic predicted protein-truncating variants in unsolved cases.
We performed further investigation of 247 individuals, in whom no pathogenic variants were detected in the known IRD-associated genes, and whose family history is not inconsistent with recessive disease.. These were screened for any gene There are several possible reasons for this. First, it may be that a higher proportion of Usher syndrome genes overall have been identified than retinitis pigmentosa genes. Second, more specific phenotypes can suggest a smaller number of candidate genes; retinitis pigmentosa is far more genetically heterogeneous than Usher syndrome. Third, it is more difficult to distinguish pathogenic monoallelic variants from the many rare benign inherited monoallelic variants, than it is to distinguish pathogenic biallelic variation, therefore phenotypes that are predominantly recessive tend to have higher pathogenic variant detection rates. Also, it may be that individuals with some phenotypes were more likely to undergo some pre-screening prior to enrolment in the project, which would exclude individuals with variants in known genes and likely reduce the pathogenic variant detection rate.
Our pathogenic variant detection rate of 56% with WGS is comparable to those previously reported in other similar studies of IRD, which ranges between 39-70%. [10] [11] [12] [13] [14] [15] 17 Factors that influence differences between these rates include the technology used and the degree of pre-screening performed on the cohort, as well as the phenotypes included and the ethnic distribution of the cohort as discussed. Our detection rate of 50% using WES in 117 individuals is perhaps lower than expected due to the WES depth of coverage of 43x used compared to diagnostic laboratory median coverage of >80x that is recommended 39 . Our observation that the subset of our cohort who had no pre-screening had a higher pathogenic variant detection rate than the overall rate, suggests that our cohort is enriched for intractable cases, and that the overall rate of 56% is an underestimate compared with what would be expected if WGS was used as the first-line test.
We have observed that using primarily WGS instead of WES or targeted gene panels has improved our power to detect three categories of variants in particular: SVs, variants in GC-rich regions, and variants in regulatory regions. Previous studies have also observed that WGS is superior to WES for the detection of SVs, particularly small deletions (e.g. single exon deletions). 6, 37, 38 This is due to high uniformity of coverage achieved with WGS, and the very high probability that the breakpoints of a SV will be covered by WGS reads. With WGS, therefore, precise characterisation of the SV to single base pair resolution is often possible, without any further investigation.
Our study also supports previous reports that PCR-free sequencing protocols, such as WGS, capture genomic regions that are particularly high or low in GC content much more effectively than methods such as WES and targeted gene panels, which require a PCR amplification step. 37, 39 GC-rich regions tend to be poorly covered by methods that require a PCR amplification step due to their high stability and consequent resistance to standard denaturation protocols, and variant calling suffers as a consequence. [40] [41] [42] The WGS analysis identified three intronic variants that would not have been identified by standard WES without specific prior knowledge. The interpretation of these variants required the availability of sequence from a large number of internal controls (~13,000 alleles from the NIHR BioResource Rare Diseases consortium) and external WGS controls (~8,000 alleles from UK10K). Frequency data on noncoding variants comparable to the ExAC dataset for coding variants is needed and will transform rare disease non-coding variant interpretation. Clinical WES platforms can be designed to target known pathogenic variants in regulatory regions in addition to the exome footprint. 43 However, they require regular redesign to capture newly reported non-coding pathogenic variants, and they do not give the option of identifying pathogenic deep intronic variants that have not been previously reported.
Regarding limitations of WGS, highly repetitive regions generally still remain poorly covered in our WGS data, due to the difficulty of uniquely mapping the reads in these regions to the genome. This has previously been reported, 17 and is also a problem for targeted gene panels and WES. 13, 14 This is an important issue for IRD, due to the existence of clinically important repetitive regions such as RPGR ORF15, which is highly repetitive, and is a mutational hotspot that constitutes one of the most common causes of X-linked retinitis pigmentosa. 44 While in the future, increasing read lengths and improved read mapping algorithms are likely to result in improved coverage over these regions, currently they must still be sequenced separately using optimised PCR amplification and Sanger sequencing protocols to exclude the possibility of them harbouring pathogenic variants. WGS also remains costlier than targeted gene panels or WES, and so currently costs more per diagnosis. 45 The authors declare no conflict of interest.
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